HPK1 inhibitor NDI-101150 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: Phase 1/2 trial results. (linkinghub.elsevier.com)

Authors: Braun DA … Sommerhalder D Journal: Cell Reports Medicine Published: 2026-05-19 DOI: https://doi.org/10.1016/j.xcrm.2026.102789